| A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases RSP Huang, J Haberberger, E Severson, DL Duncan, A Hemmerich, ... Modern Pathology 34 (2), 252-263, 2021 | 104 | 2021 |
| Comparative effectiveness of immune checkpoint inhibitors vs chemotherapy by tumor mutational burden in metastatic castration-resistant prostate cancer RP Graf, V Fisher, J Weberpals, O Gjoerup, MB Tierno, RSP Huang, ... JAMA network Open 5 (3), e225394-e225394, 2022 | 66 | 2022 |
| Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer MK Moutafi, W Tao, R Huang, J Haberberger, B Alexander, S Ramkissoon, ... Journal for immunotherapy of cancer 9 (4), 2021 | 42 | 2021 |
| Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma RSP Huang, J Haberberger, K Murugesan, N Danziger, M Hiemenz, ... Modern Pathology 34 (7), 1425-1433, 2021 | 31 | 2021 |
| Molecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin DI Lin, N Shah, YT Julie, JK Killian, A Hemmerich, C Edgerly, ... Gynecologic Oncology Reports 34, 100652, 2020 | 29 | 2020 |
| Clinicopathologic and genomic landscape of breast carcinoma brain metastases RSP Huang, J Haberberger, K McGregor, DA Mata, B Decker, ... The Oncologist 26 (10), 835-844, 2021 | 25 | 2021 |
| Targetable BRAF and RAF1 Alterations in Advanced Pediatric Cancers A Rankin, A Johnson, A Roos, G Kannan, J Knipstein, N Britt, ... The Oncologist 26 (1), e153-e163, 2021 | 24 | 2021 |
| Genomic profiling of circulating tumor DNA from cerebrospinal fluid to guide clinical decision making for patients with primary and metastatic brain tumors LA Ramkissoon, W Pegram, J Haberberger, N Danziger, G Lesser, ... Frontiers in Neurology 11, 544680, 2020 | 22 | 2020 |
| Biomarkers in breast cancer: An integrated analysis of comprehensive genomic profiling and Pd‐L1 immunohistochemistry biomarkers in 312 patients with breast cancer RSP Huang, X Li, J Haberberger, E Sokol, E Severson, DL Duncan, ... The oncologist 25 (11), 943-953, 2020 | 19 | 2020 |
| Landscape of biomarkers in non-small cell lung cancer using comprehensive genomic profiling and PD-L1 immunohistochemistry RSP Huang, E Severson, J Haberberger, DL Duncan, A Hemmerich, ... Pathology and Oncology Research 27, 2021 | 18 | 2021 |
| Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases RSP Huang, J Haberberger, E Sokol, AB Schrock, N Danziger, R Madison, ... International Journal of Cancer 148 (7), 1778-1788, 2021 | 16 | 2021 |
| Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor … BL Hill, RP Graf, K Shah, N Danziger, DI Lin, J Quintanilha, G Li, ... International Journal of Gynecologic Cancer 33 (4), 2023 | 15 | 2023 |
| Correlating ROS1 protein expression with ROS1 fusions, amplifications, and mutations RSP Huang, A Gottberg-Williams, P Vang, S Yang, N Britt, J Kaur, ... JTO Clinical and Research Reports 2 (2), 100100, 2021 | 14 | 2021 |
| FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas R Sharaf, DC Pavlick, GM Frampton, M Cooper, J Jenkins, N Danziger, ... Neuro-oncology advances 3 (1), vdab017, 2021 | 12 | 2021 |
| Clinicopathologic and genomic characterization of PD‐L1 positive urothelial carcinomas RSP Huang, J Haberberger, L Harries, E Severson, DL Duncan, ... The Oncologist 26 (5), 375-382, 2021 | 9 | 2021 |
| Genomic profiling reveals differences in primary central nervous system lymphoma and large B-cell lymphoma, with subtyping suggesting sensitivity to BTK inhibition EA Severson, J Haberberger, A Hemmerich, RSP Huang, C Edgerly, ... The Oncologist 28 (1), e26-e35, 2023 | 8 | 2023 |
| Comparative Effectiveness of Immune Checkpoint Inhibitors vs. Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer., 2022, 5, p. e225394 RP Graf, V Fisher, J Weberpals, O Gjoerup, MB Tierno, RSP Huang, ... DOI: https://doi. org/10.1001/jamanetworkopen, 2022 | 6 | 2022 |
| A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease SM Johnson, J Haberberger, J Galeotti, L Ramkissoon, CC Coombs, ... Blood Cancer Journal 13 (1), 96, 2023 | 3 | 2023 |
| Comprehensive genomic characterization of ASXL1 C. 1934dupG (p. G646fs* 12) versus other ASXL1 mutations in myeloid neoplasia SM Johnson, L Ramkissoon, J Haberberger, NL Ferguson, J Galeotti, ... Blood 138, 3466, 2021 | 3 | 2021 |
| Clinical utility of liquid-based comprehensive genomic profiling (CGP) in gastrointestinal stromal tumors (GIST). L Hildebrand, J Haberberger, R Madison, AB Schrock, JK Killian, ... Journal of Clinical Oncology 41 (16_suppl), 11541-11541, 2023 | 2 | 2023 |
